Natera(US:NTRA) Businesswire·2026-01-06 00:25Core Insights - Natera, Inc. announced new data from the ALTAIR trial will be presented at the 2026 ASCO GI Symposium, highlighting advancements in precision medicine and cell-free DNA technology [1] Group 1: ALTAIR Trial Findings - The ALTAIR trial, a randomized, double-blind, phase III study, demonstrated a statistically significant disease-free survival (DFS) benefit for Trifluridine/Tipiracil (FTD/TPI) compared to placebo in Signatera-positive patients with stage I-IV colorectal cancer, with median DFS of 9.23 months versus 5.55 months (HR: 0.75, 95% CI: 0.55-0.98; P=0.0406) [2] - This analysis represents a significant update from previous ALTAIR findings, which did not show a statistically significant DFS improvement in the full study population [2] Group 2: Prognostic Studies - Natera will present a large-scale study on Signatera velocity as a prognostic marker for relapse risk, indicating that CRC patients with Signatera levels doubling in one month or less had approximately 40% shorter recurrence-free survival compared to those with slower doubling times [3] - The prognostic association of circulating tumor DNA (ctDNA) increase and recurrence risk was significant for both patients who received adjuvant chemotherapy and those who did not [3] Group 3: Company Positioning and Future Directions - Natera's extensive evidence across various tumor types positions the company to define ctDNA dynamics, translating them into actionable clinical insights for cancer management [4] - The company aims to integrate personalized genetic testing and diagnostics into standard care, supported by over 325 peer-reviewed publications demonstrating excellent performance [10]